Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ejca.2022.05.029
Title: Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
Authors: Mai, AS
Lee, ARYB
Tay, RYK
Shapiro, L
Thakkar, A
Halmos, B
Grinshpun, A
Herishanu, Y
Benjamini, O
Tadmor, T
Shroff, RT
LaFleur, BJ
Bhattacharya, D
Peng, S
Tey, J 
Lee, SC 
Chai, LYA 
Soon, YY 
Sundar, R 
Lee, MX
Keywords: COVID-19
COVID-19 vaccine
haematological cancer
immunocompromise
solid cancer
Issue Date: 1-Sep-2022
Publisher: Elsevier BV
Citation: Mai, AS, Lee, ARYB, Tay, RYK, Shapiro, L, Thakkar, A, Halmos, B, Grinshpun, A, Herishanu, Y, Benjamini, O, Tadmor, T, Shroff, RT, LaFleur, BJ, Bhattacharya, D, Peng, S, Tey, J, Lee, SC, Chai, LYA, Soon, YY, Sundar, R, Lee, MX (2022-09-01). Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. European Journal of Cancer 172 : 65-75. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ejca.2022.05.029
Abstract: Importance: Patients with cancer have an increased risk of severe disease and mortality from COVID-19, as the disease and antineoplastic therapy cause reduced vaccine immunogenicity. Booster doses have been proposed to enhance protection, and efficacy data are emerging from several studies. Objective: To evaluate the proportion of COVID-19 primary vaccination non-responders with cancer who seroconvert after a booster dose. Methods: PubMed, EMBASE, CENTRAL and medRxiv were searched from 1st January 2021 to 10th March 2022. Quality was assessed using the Joanna Briggs Institute Critical Appraisal checklist. Results: After the eligibility assessment, 22 studies were included in this systematic review and 17 for meta-analysis of seroconversion in non-responders, pooling a total of 849 patients with haematological cancer and 82 patients with solid cancer. Haematological cancer non-responders exhibited lower seroconversion at 44% (95% CI 36–53%) than solid cancer at 80% (95% CI 69–87%). Individual patient data meta-analysis found the odds of having a meaningful rise in antibody titres to be significantly associated with increased duration between the second and third dose (OR 1.02, 95% CI 1.00–1.03, P ≤ 0.05), age of patient (OR 0.960, 95% CI 0.934–0.987, P ≤ 0.05) and cancer type. With patients with haematological cancer as a reference, patients with lung cancer had 16.8 times the odds of achieving a meaningful increase in antibody titres (OR 16.8, 95% CI 2.95–318, P ≤ 0.05) and gastrointestinal cancer patients had 25.4 times the odds of achieving a meaningful increase in antibody titres (OR 25.4, 95% CI 5.26–492.21, P ≤ 0.05). Conclusions: administration of a COVID-19 vaccine booster dose is effective in improving seroconversion and antibody levels. Patients with haematological cancer consistently demonstrate poorer response to booster vaccines than patients with solid cancer.
Source Title: European Journal of Cancer
URI: https://scholarbank.nus.edu.sg/handle/10635/229736
ISSN: 09598049
18790852
DOI: 10.1016/j.ejca.2022.05.029
Appears in Collections:Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer a systematic review and individual pati.pdf1.09 MBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

1
checked on Aug 2, 2022

Page view(s)

29
checked on Sep 29, 2022

Download(s)

6
checked on Sep 29, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.